CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

57.34 +1.91 (+3.45%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

37 38 Next >

Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares ↗

January 17, 2024

Via Benzinga

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule ↗

January 17, 2024

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...

Via Benzinga

Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units ↗

January 16, 2024

On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.

Via Benzinga

Topics ETFs

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock ↗

January 16, 2024

Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering.

Via Investor's Business Daily

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge ↗

January 16, 2024

These risky stocks can deliver big returns for investors.

Via The Motley Fool

Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

January 01, 2024

Via Benzinga

Here's Why CRISPR Therapeutics Stock Rose 54% Last Year ↗

January 15, 2024

Key regulatory developments sent this biotech stock higher.

Via The Motley Fool

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

Down 88%, Could Editas Medicine Be a Good Investment Now? ↗

January 15, 2024

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

Via The Motley Fool

What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024? ↗

January 14, 2024

An acquisition could be both a blessing and a curse for long-term investors.

Via The Motley Fool

7 Healthcare Stocks Taking Medicine to the Next Level ↗

January 14, 2024

With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider.

Via InvestorPlace

My 3 Highest-Conviction Growth Stocks to Buy in 2024 ↗

January 14, 2024

Simply put, these stocks inspire confidence.

Via The Motley Fool

My 5 Top Growth Stocks to Buy Hand Over Fist for 2024 ↗

January 14, 2024

2024 could be a year of growth.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week ↗

January 13, 2024

These companies could stand out thanks to game-changing technology.

Via The Motley Fool

2 Red Flags for Bluebird Bio Stock ↗

January 10, 2024

The biotech's struggles may continue.

Via The Motley Fool

3 Cathie Wood Stocks to Start Off Your New Year Right ↗

January 10, 2024

The following stocks could deliver big gains over time.

Via The Motley Fool

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

The Ultimate Growth Stock to Buy With $1,000 Right Now ↗

January 08, 2024

The stock, trading for about $60, has plenty of room to run.

Via The Motley Fool

5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024 ↗

January 06, 2024

You'll find exciting innovators across industries.

Via The Motley Fool

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2 Biotech Stocks With Huge Catalysts in 2024 ↗

January 05, 2024

Important clinical-trial readouts on the way could send these stocks soaring in early 2024.

Via The Motley Fool

Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors ↗

January 04, 2024

Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent.

Via InvestorPlace

Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗

January 04, 2024

CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.

Via The Motley Fool

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗

January 03, 2024

Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.

Via InvestorPlace

Better Risky Investment: Bluebird Bio vs. Shiba Inu ↗

January 03, 2024

Few investors dare to tread where the ice is known to be very thin.

Via The Motley Fool

3 Biotech Stocks Set for Breakthroughs in 2024 ↗

January 02, 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

Via InvestorPlace

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

3 No-Brainer Growth Stocks to Buy for Less Than $100 ↗

January 01, 2024

These businesses have promising futures and make for great investment options today.

Via The Motley Fool

1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗

December 31, 2023

Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.

Via The Motley Fool

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics ↗

December 31, 2023

Curing rare inherited illnesses could be a lucrative business model.

Via The Motley Fool

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.